Breaking News Instant updates and real-time market news.

NCNA

NuCana

$18.90

1.9 (11.18%)

18:25
10/21/18
10/21
18:25
10/21/18
18:25

NuCana updated Phase Ib data positive for acelarin in biliary cancer, says Piper Jaffray

Piper Jaffray analyst Joseph Catanzaro notes that NuCana presented updated Phase Ib data for Acelarin plus cisplatin in 1st-line advanced BTC at ESMO this weekend. An ORR of 50% in 14 patients is consistent with the abstract and continues to suggest a near doubling of standard of care, he adds, highlighting that tumor reductions appear to be durable out to the 36-week assessment and the safety profile is unremarkable compared to gem/cis. The analyst maintains his positive outlook for the planned Phase III trial and the opportunity to establish a new standard of care for this sizable patient population. Catanzaro reiterates an Overweight rating and $36 price target on the shares.

  • 21

    Oct

NCNA NuCana
$18.90

1.9 (11.18%)

10/18/18
PIPR
10/18/18
INITIATION
Target $36
PIPR
Overweight
NuCana initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro started NuCana with an Overweight rating and $36 price target, stating that data for its lead product, Acelarin, have "strongly" pointed towards platform validation. He sees an opportunity for the drug in platinum-resistant ovarian cancer and sees the potential for it to "establish a new frontline standard of care in biliary tract cancer," Catanzaro tells investors.
10/23/17
WBLR
10/23/17
INITIATION
WBLR
Outperform
NuCana initiated with an Outperform at William Blair
William Blair analyst Y. Katherine Xu started NuCana with an Outperform rating saying her probability-adjusted net present value model derives a fair value of $35 per share at the end of 2018 just based on the company's lead two assets. The analyst forecasts global peak sales of Acelarin in the first four indications, platinum-resistant ovarian cancer, platinum-sensitive ovarian cancer, biliary cancer, and pancreatic cancer-at GBP 800M with 40%-60% probabilities of success. She estimates NUC-3373 to generate peak sales of GBP 960M in the first two indications, advanced colorectal and breast cancers, with a 20% probability of success.
10/23/17
SBSH
10/23/17
INITIATION
Target $23
SBSH
Buy
NuCana initiated with a Buy at Citi
Citi analyst Yigal Nochomovitz started NuCana with a Buy rating and $23 price target. The company's technology platform produces "much-improved versions of decades-old chemo drugs, with minimal innovation risk," the analyst contends.
10/23/17
COWN
10/23/17
INITIATION
COWN
Outperform
NuCana initiated with an Outperform at Cowen

TODAY'S FREE FLY STORIES

PRQR

ProQR Therapeutics

$17.82

-0.84 (-4.50%)

, ONCE

Spark Therapeutics

$40.93

-1.81 (-4.23%)

07:52
11/15/18
11/15
07:52
11/15/18
07:52
Initiation
ProQR Therapeutics, Spark Therapeutics initiated  »

ProQR Therapeutics…

PRQR

ProQR Therapeutics

$17.82

-0.84 (-4.50%)

ONCE

Spark Therapeutics

$40.93

-1.81 (-4.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:50
11/15/18
11/15
07:50
11/15/18
07:50
General news
U.S. retail sales preview: »

U.S. retail sales…

O

Realty Income

$63.17

0.32 (0.51%)

07:49
11/15/18
11/15
07:49
11/15/18
07:49
Upgrade
Realty Income rating change  »

Realty Income upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRC

Spirit Realty

$8.04

-0.065 (-0.80%)

07:49
11/15/18
11/15
07:49
11/15/18
07:49
Downgrade
Spirit Realty rating change  »

Spirit Realty downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECC

Eagle Point Credit

$17.34

-0.155 (-0.89%)

07:49
11/15/18
11/15
07:49
11/15/18
07:49
Downgrade
Eagle Point Credit rating change  »

Eagle Point Credit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAFE

Safety, Income and Growth

$18.97

(0.00%)

07:49
11/15/18
11/15
07:49
11/15/18
07:49
Downgrade
Safety, Income and Growth rating change  »

Safety, Income and Growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCG

PG&E

$25.66

-7.04 (-21.53%)

07:49
11/15/18
11/15
07:49
11/15/18
07:49
Downgrade
PG&E rating change  »

Morgan Stanley cuts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPRT

Essential Properties Realty Trust

$13.96

-0.15 (-1.06%)

07:49
11/15/18
11/15
07:49
11/15/18
07:49
Downgrade
Essential Properties Realty Trust rating change  »

Essential Properties…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$44.35

-0.78 (-1.73%)

07:48
11/15/18
11/15
07:48
11/15/18
07:48
Recommendations
Cisco analyst commentary  »

Value investors should…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 10

    Jan

WLK

Westlake Chemical

$71.23

0.07 (0.10%)

07:48
11/15/18
11/15
07:48
11/15/18
07:48
Recommendations
Westlake Chemical analyst commentary  »

Westlake Chemical price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JEC

Jacobs Engineering

$73.26

-1.38 (-1.85%)

07:48
11/15/18
11/15
07:48
11/15/18
07:48
Hot Stocks
Jacobs Engineering selected by Waterbury city for wastewater utility operation »

Jacobs Engineering will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

JCP

J.C. Penney

$1.23

-0.05 (-3.91%)

07:47
11/15/18
11/15
07:47
11/15/18
07:47
Hot Stocks
Breaking Hot Stocks news story on J.C. Penney »

J.C. Penney drops 10.6%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

EPZM

Epizyme

$7.27

-0.31 (-4.09%)

07:46
11/15/18
11/15
07:46
11/15/18
07:46
Conference/Events
Epizyme to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Dec

CZR

Caesars

$8.16

0.02 (0.25%)

07:45
11/15/18
11/15
07:45
11/15/18
07:45
Initiation
Caesars initiated  »

Caesars initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

TSE

Trinseo

$46.28

1.3 (2.89%)

07:44
11/15/18
11/15
07:44
11/15/18
07:44
Upgrade
Trinseo rating change  »

Citi upgrades Trinseo to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGM

MGM Resorts

$25.94

0.2 (0.78%)

07:43
11/15/18
11/15
07:43
11/15/18
07:43
Initiation
MGM Resorts initiated  »

MGM Resorts initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 15

    Nov

  • 19

    Nov

MBRX

Moleculin Biotech

$1.29

-0.04 (-3.01%)

07:43
11/15/18
11/15
07:43
11/15/18
07:43
Hot Stocks
Moleculin Biotech files request with FDA for pre-IND meeting for WP1732 »

Moleculin Biotech…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LVS

Las Vegas Sands

$52.45

0.9 (1.75%)

07:42
11/15/18
11/15
07:42
11/15/18
07:42
Initiation
Las Vegas Sands initiated  »

Las Vegas Sands initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APRN

Blue Apron

$1.17

-0.055 (-4.51%)

07:41
11/15/18
11/15
07:41
11/15/18
07:41
Recommendations
Blue Apron analyst commentary  »

Blue Apron price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

JCP

J.C. Penney

$1.23

-0.05 (-3.91%)

07:40
11/15/18
11/15
07:40
11/15/18
07:40
Hot Stocks
J.C. Penney sees FY18 comparable store sales down low-single digits »

Comparable store sales…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

KBH

KB Home

$20.80

-0.135 (-0.64%)

07:39
11/15/18
11/15
07:39
11/15/18
07:39
Recommendations
KB Home analyst commentary  »

KB Home price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PANW

Palo Alto Networks

$176.83

-0.11 (-0.06%)

07:39
11/15/18
11/15
07:39
11/15/18
07:39
Recommendations
Palo Alto Networks analyst commentary  »

Palo Alto Networks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 19

    Nov

  • 29

    Nov

  • 10

    Dec

  • 09

    Jan

  • 10

    Jan

JCP

J.C. Penney

$1.23

-0.05 (-3.91%)

07:39
11/15/18
11/15
07:39
11/15/18
07:39
Earnings
J.C. Penney withdraws FY18 earnings guidance »

Given the company has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

KBH

KB Home

$20.80

-0.135 (-0.64%)

07:39
11/15/18
11/15
07:39
11/15/18
07:39
Recommendations
KB Home analyst commentary  »

KB Home price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WYNN

Wynn Resorts

$103.24

1.19 (1.17%)

07:37
11/15/18
11/15
07:37
11/15/18
07:37
Initiation
Wynn Resorts initiated  »

Wynn Resorts initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.